Galapagos reports Phase II CF data for GLPG2222 combo

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said cystic fibrosis candidate GLPG2222 plus Kalydeco ivacaftor significantly reduced sweat chloride levels vs. placebo plus Kalydeco in the Phase II ALBATROSS trial. The trial enrolled 37 CF patients on long-term

Read the full 350 word article

User Sign In